How to Assess Second-Line Diabetes Agents for Patients at Risk for Major Osteoporotic Fractures
What are the best ways to help prevent your type 2 diabetes patient avoid major osteoporotic fractures many diabetes medications can actually increase the risk of fracture? This interactive case study features can exploration of current science, clinical recommendations and medication options. The case study provides insights into mitigating fracture risk while effectively treating type 2 diabetes.
Respond to questions about key points in the patient's care and get expert opinions from Doron Schneider, MD, Chief Safety and Quality Officer at Abington Health and Ann V. Schwartz, Phd, MPH, Associate Professor, Department of Epidemiology and Biostatistics at the University of California San Francisco.
EARN CME CREDIT FOR THIS CASE
- Recognize factors associated with fracture risk in patients with type 2 diabetes mellitus (T2DM)
- Discuss the benefits and limitations of currently approved type 2 diabetes drug classes for patients with osteoporosis or at risk for major osteoporotic fracture (MOF)
- Explain how to assess and integrate appropriate diabetes agents for patients with T2DM at risk for MOF based on medical history, personal preferences, and glycemic goals
- Understand how to develop patient-centric management plans to maximize adherence and glycemic control, and minimize fracture risk
To claim CME credit for this case, you will need to create an account at endocrine.org if you don’t already have one.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
This activity is supported by an educational grant from Merck.
The following faculty reported relevant financial relationships:
Doron Schneider, MD: Consultant, Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Novo Nordisk Inc.
Ann V. Schwartz, PhD, MPH: Advisory board member, Amgen
The following SPC member who reviewed content for this activity reported financial relationships: Natalie Cusano, MD: Research Support, Shire; Speaker, Shire.
Endocrine Society and Knighten Health staff associated with the development of content for this activity reported no relevant financial relationships.